Physician profile
Owais Rahim
NPI 1780790626
$1,485.05
in general payments reported to CMS, 2019-2025
12 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.99 · 2022: $148 · 2023: $391 · 2024: $128 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.24 | 2022-2025 | |
| Janssen Biotech, INC. | $185.11 | 2023-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $95.93 | 2022 | |
| Novo Nordisk INC | $84.15 | 2025 | Wegovy |
| Ardelyx, INC. | $65.72 | 2025 | Ibsrela |
| Genzyme Corporation | $65.68 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.81 | 2025 | Entyvio |
| Beone Medicines USA, INC. | $46.29 | 2025 | Tevimbra |
| Pfizer INC. | $34.68 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.93 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $15.52 | 2025 | Zenpep |
| Redhill Biopharma INC. | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Owais Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.